老年患者联合用药的特点及临床药学服务模式探讨

Discussion on the Characteristics and Clinical Pharmacy Service Mode of Elderly Patients’ Combined Medication

目的分析老年患者联合用药的特点,进一步实施有针对性的临床药学服务模式,以期提高老年患者联合用药的质量及安全性。方法将我院在2017年1月至2018年1月收治的100例老年患者作为研究的对象,进一步计算、统计联合用药患者所占比重,并分析联合用药的特点情况,然后制定并实施有针对性的临床药学服务模式。结果①本次入选的100例老年患者,联合用药72例,所占比重为72.00%。②72例联合用药老年患者中,糖尿病16例(22.22%)、高血压10例(13.89%)、高血脂9例(12.50%)、冠心病8例(11.11%)、消化道溃疡疾病7例(9.72%)、心肌病6例(8.33%),2种疾病和2种以上疾病合并16例(22.22%)。结论在临床中,老年患者联合用药的比重颇高,导致老年患者联合用药的原因包括:医师、药师、护理以及患者自身,由于易出现联合用药配伍禁忌问题,进而影响联合用药的质量及安全性,因此需加强临床药学服务模式干预方案的实施,从而提高患者临床用药的合理性及安全性,进一步提高患者临床治疗疗效。

Objective To analyze the characteristics of combined drug use in elderly patients and further implement a targeted clinical pharmaceutical care model in order to improve the quality and safety of combined drug use in elderly patients.Methods 100 elderly patients admitted to our hospital from January 2017 to January 2018 were taken as the research objects.The proportion of combined drug users was further calculated and counted,and the characteristics of combined drug use were analyzed.Then the targeted clinical pharmaceutical care model was formulated and implemented.Results(1)Of the 100 elderly patients selected,72 cases were treated with combined drugs,accounting for 72.00%.(2)Among 72 elderly patients treated with combined drugs,16(22.22%)had diabetes,10(13.89%)had hypertension,9(12.50%)had hyperlipidemia,8(11.11%)had coronary heart disease,7(9.72%)had gastrointestinal ulcer disease,6(8.33%)had cardiomyopathy,and 16(22.22%)had two or more diseases.Conclusion In clinic,the proportion of combined drug use in elderly patients is quite high.The reasons for combined drug use in elderly patients include doctors,pharmacists,nursing and patients themselves.Because the incompatibility of combined drug use is easy to occur,which affects the quality and safety of combined drug use,it is necessary to strengthen the implementation of the intervention program of clinical pharmaceutical care mode,so as to improve the clinical drug use of patients.Rationality and safety to further improve the clinical efficacy of patients.